Maxim Group Initiates Coverage On Acrivon Therapeutics with Buy Rating, Announces Price Target of $24
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Michael Okunewitch has initiated coverage on Acrivon Therapeutics (NASDAQ:ACRV) with a Buy rating and a price target of $24.
October 05, 2023 | 3:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Acrivon Therapeutics has been initiated with a Buy rating by Maxim Group, with a price target of $24.
The initiation of coverage by Maxim Group with a Buy rating and a price target of $24 indicates a positive outlook for Acrivon Therapeutics. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100